PMID: 16510049Mar 3, 2006Paper

Adiposopathy is a more rational treatment target for metabolic disease than obesity alone

Current Atherosclerosis Reports
H E Bays, Carlos A Dujovne

Abstract

Current guidelines recommend that weight-loss therapy should be primarily based upon specific body mass index (BMI) cut-off limits. However, in the adipocentric paradigm, it is acknowledged that co-morbidities, such as type 2 diabetes mellitus, hypertension, and dyslipidemia, occur at all levels of BMI. Excessive fat mass (adiposity) in genetically susceptible individuals results in fat dysfunction (adiposopathy), which then contributes to metabolic disorders that increase the risk of atherosclerotic cardiovascular disease. In this paradigm, the term "anti-obesity" treatment might best be replaced by "anti-adiposopathy" treatment, wherein the focus is not based solely on BMI, but instead directed towards physiologically improving fat cell function and clinically improving the metabolic health of patients. This may occur through appropriate diet, physical exercise, and other lifestyle changes, and/or from drug therapies. Cannabinoid receptor antagonists and peroxisome proliferator activated receptor agonists are examples of agents that physiologically improve fat function and clinically improve metabolic disease.

References

Oct 1, 1982·The Journal of Clinical Investigation·P J HissinS W Cushman
Jul 23, 1998·Physiological Reviews·F M GregoireH S Sul
Aug 15, 1998·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·C Day, C J Bailey
Feb 24, 2000·The Medical Clinics of North America·N J Stone, R Kushner
Oct 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·S T NadlerA D Attie
Jan 4, 2001·The Journal of Nutrition·R F Morrison, S R Farmer
Feb 28, 2001·Diabetes, Obesity & Metabolism·K FujiokaUNKNOWN Sibutramine/Diabetes Clinical Study Group
Feb 28, 2001·Obesity Research·C D BrownM Horan
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Oct 12, 2001·Obesity Research·B MittendorferS Klein
May 8, 2002·The Journal of Clinical Endocrinology and Metabolism·Wasim A HaqueAbhimanyu Garg
Sep 13, 2002·Expert Opinion on Investigational Drugs·Harold Bays, Carlos Dujovne
Sep 17, 2002·The American Journal of Cardiology·Harold E Lebovitz
Oct 26, 2002·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Christine Ravinet TrillouPhilippe Soubrie
Nov 1, 2002·Journal of Hypertension·George BakrisUNKNOWN orlistat and resistant hypertension investigators
Nov 8, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·K C B TanK S L Lam
Apr 17, 2003·Current Opinion in Nephrology and Hypertension·Gwenn Coatmellec-Taglioni, Catherine Ribière
May 17, 2003·Science·Kitt Falk PetersenGerald I Shulman
Nov 12, 2003·Hypertension·Robert WolkVirend K Somers
Nov 14, 2003·Proceedings of the National Academy of Sciences of the United States of America·M Ehrhart-BornsteinS R Bornstein
Dec 18, 2003·The Journal of Clinical Investigation·Kathryn E Wellen, Gokhan S Hotamisligil
Dec 18, 2003·The Journal of Clinical Investigation·Stuart P WeisbergAnthony W Ferrante
Jan 27, 2004·Journal of Neuroimmunology·Thomas W KleinHerman Friedman
Feb 28, 2004·Drugs of Today·Donna H Ryan
Mar 17, 2004·Current Atherosclerosis Reports·Mehdi H Shishehbor, Deepak L Bhatt
Apr 9, 2004·The Journal of Clinical Endocrinology and Metabolism·Tongjian YouBarbara J Nicklas
May 26, 2004·Endocrinology and Metabolism Clinics of North America·Scott M Grundy
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Erin E Kershaw, Jeffrey S Flier
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Antony D KarelisEric T Poehlman
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·George A Bray
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Scott M Grundy
Jun 30, 2004·Multiple Sclerosis : Clinical and Laboratory Research·B W van OostenC H Polman

❮ Previous
Next ❯

Citations

Sep 1, 2007·Current Treatment Options in Cardiovascular Medicine·Harold BaysJ Michael González-Campoy
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Andrew J Krentz
Mar 20, 2010·Metabolic Syndrome and Related Disorders·Harold E BaysUNKNOWN SHIELD Study Group
May 12, 2007·International Journal of Clinical Practice·H E BaysUNKNOWN SHIELD Investigators' Group
Aug 7, 2008·International Journal of Clinical Practice·H E BaysUNKNOWN Adiposopathy Working Group
Aug 21, 2009·International Journal of Clinical Practice·H E BaysUNKNOWN Adiposopathy and Bariatric Surgery Working Group
Jun 6, 2014·International Journal of Endocrinology·J Michael Gonzalez-CampoyMiguel Gonzalez Ahumada
Jul 28, 2010·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·A Gastaldelli, G Basta
Jul 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Nathan A JohnsonJacob George
Jan 22, 2014·Journal of Gastroenterology and Hepatology·Cynthia TsienSrinivasan Dasarathy
Jun 24, 2010·Orvosi hetilap·Péter Apor, Attila Rádi
Jun 18, 2011·Journal of the American College of Cardiology·Harold E Bays
Oct 1, 2008·Biochemical and Biophysical Research Communications·Mireya L Herrera-Herrera, Luis A Salazar-Olivo
Dec 20, 2007·American Journal of Therapeutics·Harold E Bays, Ronald B Goldberg
Mar 19, 2009·Orvosi hetilap·Péter Apor
Dec 19, 2006·Expert Review of Cardiovascular Therapy·Harold BaysRobert Rosenson
Mar 11, 2008·Expert Review of Cardiovascular Therapy·Harold E BaysRobert R Henry
Aug 10, 2010·Nucleic Acids Research·Chatchawan Srisawat, David R Engelke
Nov 11, 2009·Expert Review of Cardiovascular Therapy·Harold E Bays
May 24, 2019·Journal of Translational Medicine·Antonino De LorenzoLaura Di Renzo
Jul 26, 2018·Frontiers in Physiology·Lingyan XuXinran Ma
Oct 1, 2019·Journal of Obesity·K Selthofer-RelatićI Bošnjak
Jul 27, 2018·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Mei-Yueh LeeShyi-Jang Shin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.